OnCusp Therapeutics: Funding, Investors & Team (Oct 2026)
OnCusp Therapeutics, founded by Bing Yuan, Eric Slosberg, and Andy Fu, is a biopharmaceutical company that utilizes advanced research assets to create innovative treatments for cancer. They constantly strive to enhance the most crucial stage in the drug development process, recognizing that accelerating the innovation of oncology medications is the most efficient approach to offer assistance and optimism to cancer patients globally.
OnCusp Therapeutics has raised $100M across 1 funding round on record, the most recent a Series A of $100M announced in Jan 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OnCusp Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2024.
OnCusp Therapeutics Funding Rounds
OnCusp Therapeutics Founders and Leadership Team
Contact details for the OnCusp Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →OnCusp Therapeutics Funding Compared to Other Biotechnology Startups
OnCusp Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OnCusp Therapeutics in Biotechnology and New York
Companies Similar to OnCusp Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
OnCusp Therapeutics Funding FAQs
What does OnCusp Therapeutics do?
OnCusp Therapeutics, founded by Bing Yuan, Eric Slosberg, and Andy Fu, is a biopharmaceutical company that utilizes advanced research assets to create innovative treatments for cancer. They constantly strive to enhance the most crucial stage in the drug development process, recognizing that accelerating the innovation of oncology medications is the most efficient approach to offer assistance and optimism to cancer patients globally.
How much funding has OnCusp Therapeutics raised?
OnCusp Therapeutics has raised $100M across 1 round on record. The most recent is a Series A of $100M announced in Jan 2024.
When did OnCusp Therapeutics last raise funding?
OnCusp Therapeutics' most recent funding round on record is a Series A of $100M, announced in Jan 2024.
Who founded OnCusp Therapeutics?
FundedIQ lists Eric Slosberg (Founder) at OnCusp Therapeutics.
Where is OnCusp Therapeutics headquartered?
OnCusp Therapeutics is based in New York, United States.
How many employees does OnCusp Therapeutics have?
OnCusp Therapeutics is in the 11-50 employee band.
How does OnCusp Therapeutics' funding compare to other Biotechnology startups?
OnCusp Therapeutics' latest round of $100M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's OnCusp Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OnCusp Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.